Upgrade to SI Premium - Free Trial

TherapeuticsMD (TXMD) Misses Q2 EPS by 6c, Revenues Beat; Raises Q3 & FY19 Revenue Guidance

August 6, 2019 5:21 PM
TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles